We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

June 3, 2022

Five Expert Insights from the HealthXL Community

Commentary
HealthXL Team & HealthXL Community

Over the past month, our HealthXL community members discussed the adoption of prescription digital therapeutics (PDTs), routes to market for digital health in oncology, and approaching investors with DTx, among other topics. We’ve put together a snapshot of five expert insights from these meetings.

#1 Adoption of prescription DTx: Even though Germany’s DiGA framework has opened a new path for reimbursement, it is not enough; significant investments in marketing and sales are needed. After being listed, the big challenge is to educate and convince doctors. No one has found the silver bullet yet, but it seems like an approach that may work is a mix of the traditional detailed promotion and innovative promotion strategies. From a sales perspective, the consultant-like model is better than the salesperson model. Companies currently listed on the DiGA and in the market are paving the path for future companies. There is the thought that it will be easier for new companies to talk to physicians since the current companies are doing the hard work of raising their awareness of digital health solutions. New companies need to consider this when future-proofing their business model. 

#2 On routes to market for digital health in oncology: The marriage of digital health and oncology is very new, with companies still figuring out the best approach. For entrepreneurs, it is important to have as many options as possible, so flexibility in approach is required. The ability to pivot between, or potentially combine, business and particular reimbursement models is something that companies should consider. One model might not be sufficient. For instance, a direct-to-consumer (D2C) approach may be required to find champions for a product, but a business-to-business (B2B) model could be needed to scale sustainably. 

#3 On DTx employer partnerships: Dealing with employers requires a different approach than with life science or medical partners. While a strong evidence base is still vital, it will be examined differently. Some of the metrics required will be less about the healthcare outcome and more about productivity, and employee satisfaction. That said, clinical trials remain important ways to illustrate the efficacy of a solution. Credibility is important and clinical evidence is often a foot in the door, even if a partner does not have the expertise to dissect it in detail. 

#4 On approaching investors with DTx: Crafting the narrative. For an early-stage company, don’t overdo the number of slides. Show a view of the finances for three years but mainly detailed for a year. The nightmare scenario for an investor is that a company can’t get to the next milestone or funding round. Companies should be careful in forecasting revenue, they often don’t meet projections and burn more cash than anticipated. Companies need to have a zoomed-out view that shows the team understands the milestones (technical, product, and team) and how each funding round delivers the company to the next stage.

#5 On combo DTx-drug clinical and economic evidence: Study design will be different depending on the moment in the drug lifecycle that a DTx is added. When designing a trial for a combo drug-DTx it will be challenging to attribute the adverse events and health benefits to either the drug or the DTx. There is no clarity on the best approach. Another big problem in some countries is regulatory bodies may not allow showing evidence with a specific commercial drug; they may ask it to be for the therapeutic area or a drug class. 

Want to join the conversation? Check out our website for upcoming meetings and events. 

Interested in more expert insights and takeaways? Become a member of our HealthXL Community for access to polls and summaries from all of our meetings. 

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

No upcoming Virtual Events scheduled. Please check back again soon.

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

26th February 2024

HealthXL @ ViVE, Los Angeles

Join the HealthXL member community at ViVE in Los Angeles on the 26th of February 2024 for an intimate, in-person breakfast discussion on the topic "What can Digital Health expect in 2024".
Featuring
5th March 2024 @ 11am ET

Tech Enabled Change in Oncology Workflows

The demand for oncology services is increasing, while the supply for oncologists is decreasing. This creates immense pressure to meet the growing demand for cancer care.

Lynda Chin
Featuring
Lynda Chin
Founder, President and CEO, Apricity Health

The Value Add of Digital Health in Pharma

The digitization across healthcare has opened up a sleuth of opportunities.
Featuring
7th March 2024 @ 11am ET

Repositioning the Role of DTx in the Industry

Repositioning the role of DTx is a complex and multifaceted task that requires addressing challenges related to reimbursement, alignment with public health priorities, clarity on pathways to market, and provider engagement.

Mike Pace
Featuring
Mike Pace
CEO & Founder, PalmHealth.co

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.